Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12521641 | 0.80 | — | — | |
| SCHEMBL31286067 | 0.80 | — | — | |
| SCHEMBL1318824 | 0.80 | — | — | |
| SCHEMBL23863 | 0.77 | — | — | |
| SCHEMBL23979001 | 0.76 | BCAT2 (0.42) | BCAT2CYP2D6CYP2C19MEN1KMT2A | |
| SCHEMBL17030141 | 0.76 | — | — | |
| SCHEMBL16103419 | 0.75 | — | — | |
| SCHEMBL2451976 | 0.75 | — | — | |
| SCHEMBL10098454 | 0.75 | — | — | |
| SCHEMBL538750 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104780902-A | Composition for external use | ROHTO PHARMA | 2015-07-15 | — | — | CN | disclosed |
| CN-102271653-B | Hair cosmetic | SHISEDO CO LTD | 2014-01-29 | — | — | CN | disclosed |
| CN-102271653-A | Hair cosmetic | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2387987-A1 | HAIR COSMETIC | Shiseido Co., Ltd. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110274642-A1 | Hair Cosmetic | SHISEIDO COMPANY, LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110255095-A1 | Optical Coherence Tomography Imaging System and Method | THORLABS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20080312304-A1 | Topical compositions containing metronidazole | ZHANG JERRY | 2008-12-18 | — | — | US | disclosed |
| US-20080287514-A1 | Topical compositions containing metronidazole | ZHANG JERRY | 2008-11-20 | — | — | US | disclosed |
| US-20080287515-A1 | Aqueous compositions containing solubilized metronidazole at a concentration of 0.75% by weight or greater are obtained by using combination of solubility enhancing agents, one of which is niacinamide and the other is hydroxyalkyl urea; treatment of dermal and mucosal disorders, for example, rosacea | ZHANG JERRY | 2008-11-20 | — | — | US | disclosed |
| US-20080081052-A1 | Topical compositions containing solubilized allantoin and related methods | ZHANG JERRY | 2008-04-03 | — | — | US | disclosed |
| US-20080057002-A1 | Non-aqueous compositions containing urea and allantoin and methods for preparing same | ZHANG JERRY | 2008-03-06 | — | — | US | disclosed |
| US-20070172436-A1 | Nonaqueous ascorbic acid compositions and methods for preparing same | ZHANG JERRY | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274642-A1 | Hair Cosmetic | H1-0, H1-5, SHH | BCAT2 1905/4885CYP2D6 3904/4885CYP2C19 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.